Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
05 janv. 2023 16h05 HE
|
Rani Therapeutics, LLC
- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of...
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study
06 déc. 2022 16h05 HE
|
Rani Therapeutics, LLC
- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO...
Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 nov. 2022 16h05 HE
|
Rani Therapeutics, LLC
- RT-102 Phase 1 topline repeat-dose data anticipated in 4Q 2022 - - Announced preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment...
Rani Therapeutics to Present at the Stifel Healthcare Conference
09 nov. 2022 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update
24 oct. 2022 08h30 HE
|
Rani Therapeutics, LLC
- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and...
Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock
11 août 2022 23h47 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the...
Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock
10 août 2022 17h28 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of...
Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update
10 août 2022 16h28 HE
|
Rani Therapeutics, LLC
- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations...
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis
10 août 2022 16h23 HE
|
Rani Therapeutics, LLC
- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events - - Bioavailability of PTH delivered via the RaniPill was found to be 300-400% greater than PTH delivered via...